Business
SCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases
New interim analysis of the Phase 3 CARES study showed complete or partial response in 78% of the 18 patients treated with ibrexafungerp for infections caused
About this update from Scynexis, Inc.
[{"type":"text","content":"New interim analysis of the Phase 3 CARES study showed complete or partial response in 78% of the 18 patients treated with ibrexafungerp for infections caused by Candida auris, a potentially deadly and multidrug-resistent pathogen with an outbreak recently reported at a Detroit specialty hospital.1 Interim data of the ongoing Phase 3 FURI and CARES studies of patients with invasive candidiasis and candidemia treated with ibrexafungerp is positive and consistent with previous analyses. Additional new in vivo data presented supports ibrexafungerp as a potential treatment for mucormycosis, a debilitating and sometimes deadly fungal infection that has seen an increase in cases globally during the COVID-19 pandemic. JERSEY CITY, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced several poster presentations highlighting details from interim analyses of data from its ongoing Phase 3 FURI and CARES studies investigating the potential of ibrexafungerp as a treatment for invasive candidiasis (IC) and candidemia, including infections caused by Candida auris (C. auris). The posters were presented at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held in Lisbon, Portugal April 23-26, 2022. “We are excited to share these latest data with the medical community as we advance our hospital clinical programs in invasive candidiasis, including candidemia,” said David Angulo, M.D. Chief Medical Officer of SCYNEXIS. “There is great unmet need for additional therapies to fight these infections, which can be quite serious, especially if the pathogen is resistant to current therapies, as can be the case with C. auris. We are proud to be a part of this important research.” C. auris, a contagious fungal infection that can quickly spread in patients in hospital wards or nursing home facilities, has been designated as an “urgent threat” by the CDC.2 Invasive C. auris infections have a high mortality rate – more than one in three patients can die.3 “Many C. auris strains are resistant to at least two classes of antifungals, which makes these interim research findings of ibrexafungerp’s activity against this terrible pathogen so promising,” said Marco ...